2020
Transgenic minipig model of Huntington's disease exhibiting gradually progressing neurodegeneration
ARDAN, Taras, Monika BAXA, Božena LEVINSKÁ, Miroslava SEDLÁČKOVÁ, The Duong NGUYEN et. al.Základní údaje
Originální název
Transgenic minipig model of Huntington's disease exhibiting gradually progressing neurodegeneration
Autoři
ARDAN, Taras (203 Česká republika), Monika BAXA (203 Česká republika), Božena LEVINSKÁ (203 Česká republika), Miroslava SEDLÁČKOVÁ (203 Česká republika, domácí), The Duong NGUYEN (203 Česká republika), Jiří KLÍMA (203 Česká republika), Štefan JUHÁS (203 Česká republika), Jana JUHÁSOVÁ (203 Česká republika), Petra ŠMATLÍKOVÁ (203 Česká republika), Petra VOCHOZKOVÁ (203 Česká republika), Jan MOTLÍK (203 Česká republika) a Zdenka ELLEDEROVÁ (203 Česká republika, garant)
Vydání
Disease models & mechanisms, Cambridge, Company of Biologists Ltd. 2020, 1754-8403
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
10601 Cell biology
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 5.758
Kód RIV
RIV/00216224:14110/20:00115361
Organizační jednotka
Lékařská fakulta
UT WoS
000518475500008
Klíčová slova anglicky
Large animal model; TgHD; Brain; Huntingtin; Neuropathology
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 15. 7. 2020 10:26, Mgr. Tereza Miškechová
Anotace
V originále
Recently developed therapeutic approaches for the treatment of Huntington’s disease (HD) require preclinical testing in large animal models. The minipig is a suitable experimental animal because of its large gyrencephalic brain, body weight of 70-100 kg, long lifespan, and anatomical, physiological and metabolic resemblance to humans. The Libechov transgenic minipig model for HD (TgHD) has proven useful for proof of concept of developing new therapies. However, to evaluate the efficacy of different therapies on disease progression, a broader phenotypic characterization of the TgHD minipig is needed. In this study, we analyzed the brain tissues of TgHD minipigs at the age of 48 and 60-70 months, and compared them to wild-type animals. We were able to demonstrate not only an accumulation of different forms of mutant huntingtin (mHTT) in TgHD brain, but also pathological changes associated with cellular damage caused by mHTT. At 48 months, we detected pathological changes that included the demyelination of brain white matter, loss of function of striatal neurons in the putamen and activation of microglia. At 60-70 months, we found a clear marker of neurodegeneration: significant cell loss detected in the caudate nucleus, putamen and cortex. This was accompanied by clusters of structures accumulating in the neurites of some neurons, a sign of their degeneration that is also seen in Alzheimer’s disease, and a significant activation of astrocytes. In summary, our data demonstrate age-dependent neuropathology with later onset of neurodegeneration in TgHD minipigs.